Drug Trial Radar · NCT04584710
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
Last checked: Nov 19, 2026Latest source record: Feb 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 13, 2020
Primary completion
Feb 2021
Study completion Feb 2021
Sponsor
- Lead sponsor
- Restorbio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Conditions
- Covid19
Interventions
RTB101Drug
Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
PlaceboDrug
Oral matching placebo once daily for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 yearsTime frame: Beginning of randomization through Week 2
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Connecticut, UConn Center on Aging
Farmington, Connecticut
Hebrew Senior Life, Marcus Institute for Aging Research
Roslindale, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.